stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.81
2.28
+7.01%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Debt to equity
Pharvaris N.V.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2020) to 0.0× (fiscal 2024); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | (12.50%) |
| FY2024 | 0.0× | 2,300.00% |
| FY2023 | 0.0× | (94.12%) |
| FY2022 | 0.0× | 142.86% |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | (30.43%) |
| Mar 2026 | 0.0× | 9.52% |
| Dec 2025 | 0.0× | 50.00% |
| Sep 2025 | 0.0× | (46.15%) |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
88
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| BHVN Biohaven Ltd. compare | −2.7× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 0.0× |
| PVLA Palvella Therapeutics, Inc. compare | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| VCEL Vericel Corporation compare | 0.0× |
| IMNM Immunome, Inc. compare | 0.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 0.0× |
| PHVS Pharvaris N.V. | 0.0× |
| CLDX Celldex Therapeutics, Inc. compare | 0.0× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)